Relative to employment protection for participants in the therapeutic cannabis program.
Impact
If enacted, HB82 will have significant implications for workplace policies regarding drug screening and the treatment of employees who are medical cannabis patients. The legislation aims to protect individuals from discrimination in hiring and employment practices related to their medical use of cannabis. Employers are expected to implement reasonable accommodations for these patients, fostering a more inclusive work environment. However, it also defines that employers can consider impairment on duty as an undue hardship, creating a balancing act between employee rights and employer obligations.
Summary
House Bill 82 (HB82) in New Hampshire is focused on providing employment protections for participants in the therapeutic cannabis program. Specifically, the bill prohibits employers from refusing to hire or terminating individuals solely based on a positive drug test for cannabis, provided these individuals are qualified patients under the therapeutic cannabis program. The legislation recognizes that having a valid registry identification card equates to a medical condition constituting a disability, thus requiring reasonable accommodations from employers unless undue hardship can be demonstrated.
Contention
Notable points of contention surrounding HB82 include discussions regarding employers' rights to maintain safe work environments versus employees' rights to access medication without fear of job loss. Critics may argue that this bill could complicate workplace drug testing procedures or lead to challenges in maintaining safety standards in certain industries. Furthermore, the bill's financial implications include potential fines for employers who violate its provisions, which some may view as an additional burden on businesses.
Relative to eligibility criteria for the therapeutic cannabis program and establishing a commission to study state-controlled sales of cannabis and relative to the prohibition on the sale of hemp products containing certain levels of THC.
Removing fees and charges for governmental records under the right-to-know law and reinstating potential liability for disclosure of information exempt from disclosure.